Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Bjørn-Erik Kristiansen a A/S Telelab, Telemark Biomedical Centre, PO Box
1868 Gulset, N-3705 Skien, Norway, b Department of Medical Microbiology, University of Tromsø,
9037 Tromsø, Norway
Correspondence to: Dr Kristiansen
bjorneri{at}online.no
| |
Abstract |
|---|
|
|
|---|
Objectives: To determine the prevalence of the
pathogenic strain of Neisseria meningitidis in contacts
of patients with meningococcal disease, and to determine which contact
groups are likely to be carriers and warrant chemoprophylaxis.
Design: Population based study.
Setting: Norwegian county of Telemark.
Subjects: 1535 primary contacts of 48 patients with
meningococcal disease, and 78 secondary contacts.
Interventions: Carriers of the pathogenic strain were
treated with rifampicin. All household members and kissing contacts under 15 years of age were treated with oral penicillin. Contacts were
taught to recognise the symptoms of meningococcal disease.
Results: In 27 of 48 cases investigated, contacts
carrying the pathogenic strain of N meningitidis were
found. A total of 42 such contacts were identified. Contacts were
stratified into three classes according to the assumed closeness of
contact with patients. In class 1 (household members and kissing
contacts) the prevalence of the pathogenic strain was 12.4% (95%
confidence interval 5.5% to 19.3%). In classes 2 and 3 the prevalence
was 1.9% (0.9% to 3.4%) and 1.6% (0.14% to 3.1%).
Conclusions: There is a high rate of carriage of the
pathogenic strain of N meningitidis in patients'
household members and kissing contacts, and this supports the practice
of giving chemoprophylaxis to these contacts. The prevalence of
carriage among other contacts is 2-3 times that found in the general
population (0.7%); the benefits of chemoprophylaxis to these contacts
may be marginal.
|
Key messages
|
| |
Introduction |
|---|
|
|
|---|
Contacts of patients with meningococcal disease have an increased risk of contracting the disease (relative risk for household members between 1000 and 4000).1-3 When meningococcal disease occurs, often carriers of the pathogenic strain of Neisseria meningitidis can be found in the patient's contacts.4-6 These carriers may develop the disease or the bacterium may spread from person to person eventually causing disease in someone without apparent link with the first patient. The frequency of secondary or associated cases has been reported as 0.5%.7 However, estimates may be higher if the time interval is extended7 or if epidemiological studies using sensitive identification techniques for bacterial strains are applied. 5 8 9 One study found 22 (9.5%) associated cases among 220 cases of meningococcal disease in Norway during 1994-96 using such methods.10
To prevent the spread of meningococcal infection, the World Health Organisation and the health authorities of most countries recommend that close contacts should receive chemoprophylaxis to eradicate the pathogenic strain.11-14 However, it may be difficult to define who is a close contact, and still more difficult to define who should be excluded from this definition. Therefore chemoprophylaxis is often given to more contacts than is needed.15 In Norway, before 1970, liberal sulphonamide chemoprophylaxis was practised. However, the emergence of a virulent clone of N meningitidis that was resistant to sulphonamide16 led the Norwegian authorities to abandon chemoprophylaxis for fear of further resistance problems. Instead, household members under 15 years of age are assumed to have meningococcal disease and are treated with penicillin orally for 1 week.17
Since November 1987 we have run the Telemark meningococcal project in which rifampicin prophylaxis is targeted to carriers of the pathogenic strains of N meningitidis identified by DNA fingerprinting of nasopharyngeal meningococci. Secondary cases have not been observed.5 We used data from this project to address the questions: "Who is most likely to carry the pathogenic strain of N meningitidis after a case of meningococcal disease?" and "To whom should chemoprophylaxis be restricted?"
| |
Subjects and methods |
|---|
|
|
|---|
The Telemark project
The detailed organisation of this project has been described
previously.5 After isolation of meningococci from a
patient specimen the local health officer is alerted, who then collects throat samples from members of the patient's household before initiating penicillin treatment to those under 15 years of
age.17 Parents accompanying the patient to hospital are
often sampled by the hospital staff.
Both tonsils and the posterior
pharyngeal surface were sampled with a cotton swab, plated immediately
on GC agar base (Mast Diagnostics, Merseyside, UK) supplemented with
haematin, 1% IsoVitalex (BBL, Cockeysville, MD,USA), vancomycin
(3 mg/l), and colistin (7.5 mg/l), and incubated at 37°C in 10%
carbon dioxide within two hours of sampling. Wherever possible,
sampling was done by two of the authors (BK and YT).
Identification of the pathogenic strain
Contacts carrying a
meningococcus with a chromosomal DNA fingerprint identical to that of
the patient isolate were identified as previously
described18 and were defined as carrying the pathogenic strain (fig).
|
Statistical methods
Confidence intervals for the prevalence of the pathogenic strain
were calculated as follows:
|
(Eq. 1) |
|
(Eq. 2) |
|
|
| |
Results |
|---|
|
|
|---|
From 1 November 1987 to 1 December 1996 there were 48 cases (cases 3-50) of meningococcal disease
in the county of Telemark, Norway, verified bacteriologically (table
1). Thirty isolates were serogroup B, 14 were serogroup C, three were
serogroup Y, and one was serogroup W135. Twenty four of the patients
were under 4 years of age. The remaining cases were distributed in the
age groups 5-12 years (six cases), 13-18 years (nine), 19-60 years (five), and >60 years
(four).
|
|
|
Classification of contacts into groups and classes
We
collected throat specimens from 1535 close contacts (primary contacts)
of the patients, and from 78 secondary contacts who were household
members or kissing contacts of primary contacts found to carry the
pathogenic strain. All contacts approached consented to sampling. The
primary contacts were divided into 16 contact groups and further
organised into three classes according to the degree of contact with
the patient (tables 2 to 4). Class 1 consists of household members and
kissing contacts, the groups of contacts assumed to have the closest
contact with the patient. Class 2 contacts are considered to have
closer contact with the patient than class 3 contacts. Secondary
contacts were placed in a separate group, group 18 (table
5).
|
|
Carrier rate
Among 1535 primary contacts, 234 meningococcal
carriers were found. Of these, 42 carried the pathogenic strain. Thirty
six of the 145 class 1 contacts carried meningococci. The pathogenic strain was found in 18 (12.4%: 95% confidence interval 5.5% to 19.3%) of these contacts: 6/37 (16.2%) mothers, 5/37 (13.5%)
fathers, 4/29 (13.8%) brothers, 1/21 (4.8%) sisters, 1/18 (5.5%)
other household members, and 1/3 (33.3%) kissing contacts. Of 576 class 2 contacts, 105 (18.2%) carried meningococci. The pathogenic
strain was found in 11 (1.9%: 0.9% to 3.4%). Of 814 class 3 contacts, 93 (11.4%) carried meningococci. The pathogenic strain was
found in 13 (1.6%: 0.14% to 3.1%) of these contacts. Of 78 secondary contacts, 20 (25.6%) carried meningococci. The pathogenic strain was
found in four (5.1%) of these contacts.
The pathogenic strain was found in the primary contacts of 27 of the 48 patients, the number of carriers varying between 1 and 6 (table 5). The pathogenic strain was found more often in contacts in the 5-12 years age group than in the other age groups (table 1).
| |
Discussion |
|---|
|
|
|---|
In most countries the use of chemoprophylaxis is recommended to prevent secondary disease in close contacts of patients with meningococcal disease.11-14 In a few other countries, including Norway, chemoprophylaxis is not recommended, but household members under 15 years of age are treated with penicillin orally.17 Neither approach has been evaluated in controlled studies.
When a case of meningococcal disease occurs, many people may fulfill accepted criteria for receiving chemoprophylaxis,11-14 and chemoprophylaxis may be prescribed in excess of what is needed.14 High consumption of chemoprophylactic agents may select bacterial resistance, which in meningococci may be associated with virulence.19 Chemoprophylactic agents may also kill non-virulent meningococci and other bacteria that stimulate an immune response against the meningococci.20 Chemoprophylaxis should therefore be restricted to those who are likely to carry the pathogenic strain.
Our study shows that only 42 (2.7%) of 1535 close contacts carried the pathogenic strain of N meningitidis. General use of chemoprophylaxis in all these contacts therefore seems excessive. Sensitive and rapid techniques for identification of the pathogenic strain 8 9 allow targeting of chemoprophylaxis to carriers, but have not yet been widely applied as most laboratories lack the technology and resources to perform these tests. In most cases, therefore, the decision of whether to give chemoprophylaxis must be made on the basis of closeness of contact with the patient.
Our study shows that the risk of carriage of the pathogenic strain is highest (12.4%, 95% confidence interval 5.5% to 19.3%) in household members and kissing contacts. Household members have a high relative risk of meningococcal disease (1000-40001-3) and the use of chemoprophylaxis in this group therefore seems well justified. Contacts outside this group, most of whom qualified for chemoprophylaxis according to accepted criteria,11-14 had a considerably lower prevalence of carriage of the pathogenic strain (class 2, 1.9%, 0.9% to 3.4%; class 3, 1.6%, 0.14% to 3.1%). This is higher than the 0.7% prevalence in the general population, during periods of low disease incidence, 18 21 but not dramatically so. Should these contacts receive chemoprophylaxis? Our results do not support this practice. However, the relative risk of meningococcal disease is over 1000 for household members, although our results indicate that the carriage rate (12.4%) is only 18 times higher than that found in the general population (0.7%) in other studies. The relative risk of meningococcal disease is therefore not a simple function of the prevalence of the pathogenic strain. Another way to view the problem would be to ask whether the prevalence of the pathogenic strain approaches that needed to initiate epidemic disease. It has been suggested that a high rate of carriage is a prerequisite for epidemic disease,22 but the threshold is not known, and in any case the prevalence will vary from case to case. We therefore feel that the choice of whether to give chemoprophylaxis to contacts outside the patient's household and kissing contacts should be made on an individual basis, taking into account: other cases in the vicinity or other reasons to suspect an outbreak in the community; a high incidence of influenza or other respiratory infection that may predispose contacts to meningococcal disease and mask the symptoms of early infection; and other predisposing factors. If, however, an isolated case occurs in an otherwise healthy community, we believe that a conservative approach to chemoprophylaxis is justified.
Our study illustrates the need for better understanding of the relation between carrier rate and risk of secondary disease. A controlled study comparing different chemoprophylaxis strategies would in our view be of considerable help. The following strategies should be considered: (a) chemoprophylaxis according to standard recommendations, (b) chemoprophylaxis given only to household members and kissing contacts, and (c) chemoprophylaxis given to household members, kissing contacts, and other close contacts who are found to carry the pathogenic strain. Cost benefit analysis and studies of the prevalence of the pathogenic strain would enhance the value of such a study.
It has been argued that throat swabbing underestimates the true rate of
meningococcal carriage.23 Low levels of bacteria in the
sample, loss of viability under transport, and variable sampling
techniques can all influence the measured carrier rate, but sampling
and transport are probably the more important factors.24 We have addressed this problem by attempting to confine sampling to two
well trained members of our staff, by plating samples directly after
collection, and by sampling the throat, which has been reported to have
100% sensitivity relative to other sampling sites.25 A
minority of the samples were collected by hospital and clinic staff and
transported before plating. These are almost exclusively samples
collected from members of the patient's household
that is, the group
where we found the highest rates of carriage. Serious underestimation
of carriage might be expected to lead to secondary cases among the
contacts we sampled. None of the 1535 primary and 78 secondary contacts
contracted meningococcal disease. We therefore do not think that
sampling problems seriously affect this
study.
| |
Acknowledgments |
|---|
Contributors: B-EK had the original idea for the present study, collected samples, and wrote the manuscript. Randi Kersten (A/S Telelab, Skien, Norway) analysed the data and wrote an initial manuscript as part of her magisterial dissertation in microbiology, Anne Gry Allum (A/S Telelab) assisted in sample collection and performed DNA fingerprinting, YT collected samples and helped with data analysis. AJ took an active part in the analysis and discussion of data, and in writing the manuscript. Statistical analysis was conducted by Tone Grande (Mericon A/S, Skien, Norway). A theoretical analysis of the problem of estimating confidence intervals in this data set was provided by Professor Nils Lid Hjort, University of Oslo. The Telemark project was started by Arne-Birger Knapskog, country health officer, Skien, Norway. B-EK and AJ will act as guarantors for the paper.
Funding: This project is a part of A/S Telelab's internally funded research programme.
Conflict of interest: None.
| |
References |
|---|
|
|
|---|
(Accepted 6 July 1998)
Read all Rapid Responses